Association of patient and disease characteristics with outcomes of regorafenib in patients with metastatic colorectal cancer.

被引：0
|
作者：
Hsieh, Ronan Wenhan
Lee, Matthew
Johnson, Devin
Zhang, Chenxin
Moon, Jee-Young
Hsu, Dennis
Acuna-Villaorduna, Ana
Kuang, Chaoyuan
机构：
[1] Univ Pittsbugh, Med Ctr, Pittsburgh, PA USA
[2] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA
[3] Albert Einstein Coll Med, Bronx, NY 10467 USA
[4] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
135
引用
收藏
页码：135 / 135
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness (CE) of regorafenib dose optimization schedule in metastatic colorectal cancer.
    Barzi, Afsaneh
    Cho, Sang K.
    Hay, Joel W.
    Lenz, Heinz-Josef
    Ou, Fang-Shu
    Grothey, Axel
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Perioperative therapy in patients with metastatic colorectal cancer.
    Alese, Olatunji B.
    Zakka, Katerina Mary
    Huo, Xingyue
    Jiang, Renjian
    Shaib, Walid Labib
    Wu, Christina
    Akce, Mehmet
    Sullivan, Patrick S.
    Behera, Madhusmita
    El-Rayes, Bassel F.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [33] Treatment Outcomes in Patients Receiving Regorafenib for Metastatic Colon Cancer
    Fok, L.
    Cheung, K. M.
    Kwok, Y. L.
    Wong, K. H.
    HONG KONG JOURNAL OF RADIOLOGY, 2020, 23 (01): : 12 - 19
  • [34] Clinical Outcomes Following Trifluridine/Tipiracil Treatment for Patients With Metastatic Colorectal Cancer Ineligible for Regorafenib Treatment
    Niisato, Yusuke
    Moriwaki, Toshikazu
    Fukuoka, Shota
    Masuishi, Toshiki
    Takashima, Atsuo
    Kumekawa, Yosuke
    Kajiwara, Takeshi
    Yamazaki, Kentaro
    Esaki, Taito
    Makiyama, Akitaka
    Denda, Tadamichi
    Hatachi, Yukimasa
    Suto, Takeshi
    Sugimoto, Naotoshi
    Shimada, Yasuhiro
    ANTICANCER RESEARCH, 2021, 41 (04) : 2203 - 2207
  • [35] Outcomes and predictive factors of regorafenib benefit in patients with metastatic colorectal cancer in a real-life setting
    Martinez Lago, N.
    Carnero Lopez, B.
    De la Camara Gomez, J.
    Vazquez-Rivera, F.
    Fernandez Montes, A.
    de Dios, N.
    Carral Maseda, A.
    Pellon Augusto, M.
    Candamio Folgar, S.
    Reboredo-Lopez, M.
    Salgado Fernandez, M.
    Gallardo Martin, E.
    Covela-Rua, M.
    Grana Suarez, B.
    Carmona Campos, M.
    Brozos Vazquez, E.
    Reboredo Rendo, C.
    Quintero Aldana, G.
    Grande Ventura, C.
    Vidal Insua, Y.
    Mendez Mendez, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S130 - S130
  • [36] Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management
    Khan, Gazala
    Moss, Rebecca A.
    Braiteh, Fadi
    Saltzman, Marc
    CANCER MANAGEMENT AND RESEARCH, 2014, 6 : 93 - 103
  • [37] Colorectal Cancer Regorafenib in metastatic, pretreated Tumors
    Krome, Susanne
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2013, 51 (06): : 530 - 530
  • [38] Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer
    Kim, Seung Tae
    Kim, Tae Won
    Kim, Kyu-Pyo
    Kim, Tae-You
    Han, Sae-Won
    Lee, Ji Yun
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Haesu
    Park, Young Suk
    CANCER RESEARCH AND TREATMENT, 2015, 47 (04): : 790 - 795
  • [39] Oral multikinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer
    Cremolini, Chiara
    Schirripa, Marta
    Loupakis, Fotios
    Falcone, Alfredo
    COLORECTAL CANCER, 2013, 2 (05) : 411 - 417
  • [40] Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib
    Vincenzo Ricci
    Cristina Granetto
    Antonella Falletta
    Matteo Paccagnella
    Andrea Abbona
    Elena Fea
    Teresa Fabozzi
    Cristiana Lo Nigro
    Marco Carlo Merlano
    World Journal of Gastrointestinal Oncology, 2020, (03) : 301 - 310
12345